JP2020514359A5 - - Google Patents

Download PDF

Info

Publication number
JP2020514359A5
JP2020514359A5 JP2019550634A JP2019550634A JP2020514359A5 JP 2020514359 A5 JP2020514359 A5 JP 2020514359A5 JP 2019550634 A JP2019550634 A JP 2019550634A JP 2019550634 A JP2019550634 A JP 2019550634A JP 2020514359 A5 JP2020514359 A5 JP 2020514359A5
Authority
JP
Japan
Prior art keywords
composition
cancer
nanoparticles
skin
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019550634A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020514359A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/022540 external-priority patent/WO2018170196A1/en
Publication of JP2020514359A publication Critical patent/JP2020514359A/ja
Publication of JP2020514359A5 publication Critical patent/JP2020514359A5/ja
Priority to JP2023103829A priority Critical patent/JP2023120393A/ja
Pending legal-status Critical Current

Links

JP2019550634A 2017-03-15 2018-03-15 タキサンのナノ粒子を用いる皮膚悪性腫瘍処置のための局所療法 Pending JP2020514359A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023103829A JP2023120393A (ja) 2017-03-15 2023-06-26 タキサンのナノ粒子を用いる皮膚悪性腫瘍処置のための局所療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762471561P 2017-03-15 2017-03-15
US62/471,561 2017-03-15
PCT/US2018/022540 WO2018170196A1 (en) 2017-03-15 2018-03-15 Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023103829A Division JP2023120393A (ja) 2017-03-15 2023-06-26 タキサンのナノ粒子を用いる皮膚悪性腫瘍処置のための局所療法

Publications (2)

Publication Number Publication Date
JP2020514359A JP2020514359A (ja) 2020-05-21
JP2020514359A5 true JP2020514359A5 (enExample) 2021-04-08

Family

ID=61911679

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019550634A Pending JP2020514359A (ja) 2017-03-15 2018-03-15 タキサンのナノ粒子を用いる皮膚悪性腫瘍処置のための局所療法
JP2023103829A Pending JP2023120393A (ja) 2017-03-15 2023-06-26 タキサンのナノ粒子を用いる皮膚悪性腫瘍処置のための局所療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023103829A Pending JP2023120393A (ja) 2017-03-15 2023-06-26 タキサンのナノ粒子を用いる皮膚悪性腫瘍処置のための局所療法

Country Status (8)

Country Link
US (4) US10555898B2 (enExample)
EP (1) EP3595633B1 (enExample)
JP (2) JP2020514359A (enExample)
KR (1) KR102658256B1 (enExample)
CN (2) CN118948828A (enExample)
CA (1) CA3056395C (enExample)
ES (1) ES2955884T3 (enExample)
WO (1) WO2018170196A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3026454C (en) 2015-06-04 2023-07-04 Crititech, Inc. Collection device and methods for use
CN114588270B (zh) 2015-09-16 2024-08-06 Dfb索里亚有限责任公司 包含紫杉烷类纳米颗粒的组合物及其用途
BR112018069628A2 (pt) 2016-04-04 2019-02-12 Crititech, Inc. métodos para tratamento de tumor sólido
EP3595633B1 (en) 2017-03-15 2023-07-05 DFB Soria, LLC Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes
SG11201909840TA (en) 2017-06-09 2019-11-28 Crititech Inc Treatment of epithelial cysts by intracystic injection of antineoplastic particles
KR102303762B1 (ko) 2017-06-14 2021-09-23 크리티테크, 인크. 폐 장애의 치료 방법
WO2019070850A1 (en) 2017-10-03 2019-04-11 Crititech, Inc. LOCAL ADMINISTRATION OF ANINEOPLASTIC PARTICLES IN COMBINATION WITH SYSTEMIC DELIVERY OF IMMUNOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER
US11497726B2 (en) 2018-03-16 2022-11-15 Dfb Soria, Ll. Topical therapy for the treatment of cervical intraepithelial neoplasia (CIN) and cervical cancer using nanoparticles of taxanes
US20190365698A1 (en) * 2018-05-31 2019-12-05 Crititech, Inc. Use of Antineoplastic Agents to Stimulate the Immune System for Treatment of Cancer
US20220273530A1 (en) * 2019-08-29 2022-09-01 Skinosive Bioadhesive particles comprising active agents, and uses thereof
WO2021056106A1 (en) * 2019-09-23 2021-04-01 Dds Research Inc. Lipid vesicle compositions with penetration enhancing agents
KR20240035939A (ko) 2021-03-24 2024-03-19 글로 파마, 인크. 피부 색소침착을 감소시키기 위한 펩타이드 및 방법
CN120818186B (zh) * 2025-09-12 2025-11-18 四川大学 一种基于深共晶体系的聚轮烷材料及其制备方法和应用

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
NZ268326A (en) 1993-07-19 1997-12-19 Angiogenesis Tech Inc Stent with a coating comprising an anti-angiogenic compound, such as taxol, and a polymeric carrier
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US5874029A (en) 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
AU737078C (en) 1996-05-24 2002-05-02 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing diseases of body passageways
CA2189916C (en) 1996-11-08 2001-01-16 Parkash S. Gill A new regime for paclitaxel in kaposi's sarcoma patients
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
CN100462066C (zh) 1997-06-27 2009-02-18 美国生物科学有限公司 药剂的新制剂及其制备和应用方法
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6117949A (en) 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
IL131217A0 (en) 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US6113795A (en) 1998-11-17 2000-09-05 The University Of Kansas Process and apparatus for size selective separation of micro- and nano-particles
IN191203B (enExample) 1999-02-17 2003-10-04 Amarnath Prof Maitra
US6365191B1 (en) 1999-02-17 2002-04-02 Dabur Research Foundation Formulations of paclitaxel, its derivatives or its analogs entrapped into nanoparticles of polymeric micelles, process for preparing same and the use thereof
US6406722B1 (en) 1999-02-18 2002-06-18 Robert G. Gallaher Method of treating viral infections and lesions with taxane compounds
US7217735B1 (en) 1999-04-09 2007-05-15 Au Jessie L-S Methods and compositions for enhancing delivery of therapeutic agents to tissues
ATE312601T1 (de) 1999-05-27 2005-12-15 Acusphere Inc Poröse arzneistoffmatrizen und deren herstellungsverfahren
US6610317B2 (en) 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
US6892091B1 (en) 2000-02-18 2005-05-10 Biosense, Inc. Catheter, method and apparatus for generating an electrical map of a chamber of the heart
EP1301500B1 (en) 2000-06-22 2007-11-21 Nitromed, Inc. Nitrosated and nitrosylated taxanes, compositions and methods of use
US20040022862A1 (en) 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US8178123B2 (en) 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
AU2002329842B2 (en) 2001-08-29 2006-09-14 Umd, Inc. Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
WO2003032906A2 (en) 2001-10-15 2003-04-24 Crititech, Inc. Delivery of poorly soluble drugs
US20080220075A1 (en) 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
DE60309300T3 (de) 2002-03-20 2011-02-24 Elan Pharma International Ltd. Nanopartikelzusammensetzungen von angiogeneseinhibitoren
KR100533458B1 (ko) 2002-07-20 2005-12-07 대화제약 주식회사 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
EP1569620A4 (en) 2002-10-30 2006-03-22 Spherics Inc NANOPARTICULAR BIOACTIVE AGENTS
DK1585548T3 (en) 2002-12-09 2018-09-03 Abraxis Bioscience Llc COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
FR2856301B1 (fr) 2003-06-23 2007-08-03 Galderma Res & Dev Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile
US9149440B2 (en) 2003-09-02 2015-10-06 University Of South Florida Nanoparticles for drug-delivery
PT2286794T (pt) 2003-10-15 2016-07-13 Syncore Biotechnology Co Ltd Uso de lipossomas catiónicos contendo placlitaxel
ES2366646T3 (es) 2003-11-05 2011-10-24 Elan Pharma International Limited Composiciones en forma de nanopartículas que tienen un péptido como estabilizante superficial.
FR2862540B1 (fr) 2003-11-21 2007-03-30 Galderma Res & Dev Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile
FR2871695B1 (fr) 2004-06-17 2008-07-04 Galderma Sa Composition pharmaceutique comprenant un agent silicone et deux principes actifs solubilises
FR2871697B1 (fr) 2004-06-17 2007-06-29 Galderma Sa Composition sous forme de spray comprenant une association d'actifs pharmaceutiques, une phase alcoolique, au moins un silicone volatile et une phase huileuse non volatile
US7361683B2 (en) 2004-11-24 2008-04-22 Yung Shin Pharm. Ind., Co., Ltd Paclitaxel aqueous injection solution and methods for preparing the same
US8062658B2 (en) 2004-12-14 2011-11-22 Poly-Med, Inc. Multicomponent bioactive intravaginal ring
BRPI0608173A2 (pt) 2005-02-24 2010-11-09 Elan Pharma Int Ltd composição, uso da mesma, e, método de produzir uma composição de docetaxel nanoparticulada ou análogo do mesmo
CN101151028A (zh) * 2005-03-03 2008-03-26 Isw集团公司 局部用凝胶组合物
GB0506139D0 (en) 2005-03-24 2005-05-04 Transphase Ltd A transdermal topical composition and its uses
ES2363247T3 (es) 2005-04-27 2011-07-28 Leiden University Medical Center Tratamiento para neoplasias intraepiteliales anogenitales inducidas por vph.
US20090304803A1 (en) 2005-06-06 2009-12-10 The General Hospital Corporation Compositions and methods relating to target-specific photodynamic therapy
US8034765B2 (en) 2005-08-31 2011-10-11 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
WO2007070850A2 (en) 2005-12-14 2007-06-21 Organogenesis, Inc. Skin care compositions and treatments
US8906392B2 (en) 2005-12-16 2014-12-09 University Of Kansas Nanocluster compositions and methods
US8343962B2 (en) 2006-03-06 2013-01-01 Nuvo Research Inc. Topical formulation
WO2008070279A2 (en) 2006-10-11 2008-06-12 Crititech, Inc. Method for precipitation of small medicament particles into use containers
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
CA2611803C (en) 2006-11-22 2013-03-19 Bj Services Company Well treatment fluid containing viscoelastic surfactant and viscosification activator
JP5933893B2 (ja) 2006-12-14 2016-06-15 アブラクシス バイオサイエンス, エルエルシー ホルモン受容体状態に基づいてタキサンを含むナノ粒子用いる乳癌治療法
TWI405590B (zh) 2007-04-06 2013-08-21 Activus Pharma Co Ltd 微粉碎化有機化合物粒子之製法
AU2008260447B2 (en) 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
ITMI20071267A1 (it) 2007-06-22 2008-12-23 Fidia Farmaceutici Uso di coniugati dell'acido ialuronico nel trattamento locale di malattie cutanee iperproliferative
HU227970B1 (en) 2007-07-10 2012-07-30 Egis Gyogyszergyar Nyrt Pharmaceutical compositions containing silicones of high volatility
GB0716591D0 (en) * 2007-08-24 2007-10-03 Vereniging Het Nl Kanker I Composition
CN101129338A (zh) 2007-08-27 2008-02-27 四川大学 超临界流体新技术微细化抗癌药物紫杉醇
PL2200588T3 (pl) 2007-09-25 2019-09-30 Solubest Ltd. Kompozycje zawierające lipofilowe związki aktywne i sposób ich wytwarzania
KR101563658B1 (ko) 2007-11-28 2015-10-27 셀라토 파마슈티칼즈, 인코포레이티드 개선된 탁산 전달 시스템
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
US8865194B1 (en) 2007-12-20 2014-10-21 Theraplex Company, LLC Reducing tackiness and greasiness of petrolatum-like materials
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
US8952075B2 (en) 2008-05-22 2015-02-10 Poly-Med, Inc. Bioactive polymeric liquid formulations of absorbable, segmented aliphatic polyurethane compositions
WO2009153774A2 (en) 2008-06-17 2009-12-23 Rosetta Genomics Ltd. Compositions and methods for prognosis of ovarian cancer
KR20160130519A (ko) 2008-06-26 2016-11-11 안테리오스, 인코퍼레이티드 경피 운반
ES2958410T3 (es) 2009-08-21 2024-02-08 Novan Inc Geles tópicos
WO2011039637A2 (en) 2009-10-02 2011-04-07 Foamix Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
GB2474930B (en) * 2009-10-02 2012-07-04 Foamix Ltd Topical tetracycline compositions
BR112012008772A2 (pt) 2009-10-13 2017-06-20 Rexahn Pharmaceuticals Inc sistemas poliméricos para a liberação de agentes anti-câncer
CN101829061A (zh) 2010-05-14 2010-09-15 无锡纳生生物科技有限公司 一种紫杉醇纳米颗粒组合物及其制备方法
CN101843582B (zh) 2010-05-18 2011-12-21 南京工业大学 紫杉醇纳米混悬剂及其制备方法
WO2011151418A2 (en) 2010-06-02 2011-12-08 Abbott Gmbh & Co. Kg Nanosusupension formulation comprising a polydimethylsiloxane hydrophobic phase
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
US20130211384A1 (en) 2010-07-28 2013-08-15 Fondazione Irccs Istituto Nazionale Dei Tumori Therapeutic agent, composition including said agent, implantable device and process for the treatment of cervical cancer and/or for the prevention of the formation of neoplasms in correspondence of the cervix in a human female genital system
US20130267490A1 (en) 2010-08-02 2013-10-10 Ranbaxy Laboratories Limited Topical pharmaceutical composition comprising nanonized silver sulfadiazine and chlorhexidine gluconate
US8563535B2 (en) 2011-03-29 2013-10-22 Kamal Mehta Combination composition comprising benzoyl peroxide and adapalene
WO2012130314A1 (en) 2011-03-31 2012-10-04 Elara Pharmaceuticals Gmbh Composition comprising docetaxel
KR20140024292A (ko) 2011-04-01 2014-02-28 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 치료제의 국소 전달용 감열성, 점막부착성 또는 표피부착성, 및 침투강화성 제제
US20140073615A1 (en) 2011-05-02 2014-03-13 Lipidor Ab Treatment of Psoriasis
WO2013002636A1 (en) 2011-06-27 2013-01-03 Cristal Delivery B.V. Controlled release system
US20130337070A1 (en) * 2012-05-25 2013-12-19 University Of Central Florida Research Foundation Inc. Coated Nanoparticle Therapy for Skin Cancer
US9018246B2 (en) 2012-09-05 2015-04-28 Lp Pharmaceutical (Xiamen) Co., Ltd. Transmucosal administration of taxanes
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
JP2014114249A (ja) 2012-12-11 2014-06-26 Kanae Technos:Kk 基剤、及び皮膚外用剤
GB2511115A (en) * 2013-02-25 2014-08-27 Linde Ag An end port regenerative furnace
US8778181B1 (en) 2013-03-14 2014-07-15 Crititech, Inc. Equipment assembly for and method of processing particles
EP2978420A4 (en) 2013-03-28 2016-12-21 Bbs Nanotechnology Ltd STABLE NANO COMPOSITION WITH DOXORUBICIN, PROCESS FOR THE PREPARATION THEREOF, THE USE THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREWITH
BR112015032758A2 (pt) 2013-06-28 2017-07-25 Bind Therapeutics Inc nanopartículas poliméricas de docetaxel para o tratamento de câncer
TWI601542B (zh) 2014-04-18 2017-10-11 林信湧 一種用於治療肺癌之吸入式醫藥組成物及其備製方法
WO2015187194A1 (en) 2014-06-01 2015-12-10 Crititech, Inc. Use of paclitaxel particles
WO2016071365A1 (en) 2014-11-03 2016-05-12 Spherium Biomed, S.L. Topical pharmaceutical compositions of paclitaxel
CN105280869B (zh) 2015-01-07 2018-07-31 保定钰鑫电气科技有限公司 一种组合式蓄电池端子连接片
CA3026454C (en) 2015-06-04 2023-07-04 Crititech, Inc. Collection device and methods for use
CN114588270B (zh) 2015-09-16 2024-08-06 Dfb索里亚有限责任公司 包含紫杉烷类纳米颗粒的组合物及其用途
CN105380869A (zh) * 2015-12-28 2016-03-09 深圳中农科工创业资产管理有限公司 一种纳米红豆杉护肤品及其用途
BR112018069628A2 (pt) 2016-04-04 2019-02-12 Crititech, Inc. métodos para tratamento de tumor sólido
EP3595633B1 (en) * 2017-03-15 2023-07-05 DFB Soria, LLC Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes

Similar Documents

Publication Publication Date Title
JP2020514359A5 (enExample)
JP2023120393A5 (enExample)
JP2018531231A5 (enExample)
JP2011246704A5 (enExample)
WO2014022363A3 (en) Anti-smudge hard coat and anti-smudge hard coat precursor
JP2013531621A5 (enExample)
HK1254909A1 (zh) 药物纳米粒子的传送及其使用方法
Mikhailov Synthesis of 3d-element metalmacrocyclic chelates into polypeptide biopolymer medium and their molecular structures
EA200801132A1 (ru) Новые улучшенные композиции для лечения рака
RU2010145056A (ru) Соли бис (тиогидразидамида) для лечения рака
WO2007139930A3 (en) Drug combinations with substituted diaryl ureas for the treatment of cancer
CN113366008A (zh) 一种cd73抑制剂,其制备方法和应用
JP2013527232A5 (enExample)
JP2009035511A5 (enExample)
BR112015032758A2 (pt) nanopartículas poliméricas de docetaxel para o tratamento de câncer
JP2011506257A5 (enExample)
JP2019534865A5 (enExample)
RU2020110399A (ru) Местная доставка противоопухолевых частиц в комбинации с системной доставкой иммунотерапевтических агентов для лечения рака
JP6355078B2 (ja) 有機シラン化合物の製造方法及び有機シラン化合物合成用触媒組成物
WO2018131430A1 (ja) 金属元素含有ナノ粒子を用いたヒドロシリル化による有機ケイ素化合物の製造方法
Hamacher Recorded accounts of meteoritic events in the oral traditions of Indigenous Australians
JP2021517906A5 (enExample)
JP2013234133A5 (enExample)
JPWO2019178024A5 (enExample)
TR201814012A2 (tr) Suda çözünebilen, agregasyon göstermeyen akciğer, karaciğer, meme ve melanoma kanser türlerine karşı ın vıtro antikanser etkili yeni bir silisyum ftalosiyanin bileşiği.